{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:11:43Z","timestamp":1779527503433,"version":"3.53.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T00:00:00Z","timestamp":1766361600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2024"],"award-info":[{"award-number":["Ricerca Corrente 2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2024"],"award-info":[{"award-number":["Ricerca Corrente 2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2024"],"award-info":[{"award-number":["Ricerca Corrente 2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2024"],"award-info":[{"award-number":["Ricerca Corrente 2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2024"],"award-info":[{"award-number":["Ricerca Corrente 2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003196","name":"Ministero della Salute","doi-asserted-by":"publisher","award":["Ricerca Corrente 2024"],"award-info":[{"award-number":["Ricerca Corrente 2024"]}],"id":[{"id":"10.13039\/501100003196","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurogenetics"],"DOI":"10.1007\/s10048-025-00874-z","type":"journal-article","created":{"date-parts":[[2025,12,22]],"date-time":"2025-12-22T10:12:21Z","timestamp":1766398341000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Miglustat does not impact clinical progression in patients with spastic paraplegia type 11"],"prefix":"10.1007","volume":"27","author":[{"given":"Serena","family":"Mero","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ivana","family":"Ricca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Salvatore","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabato","family":"Mellone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olimpia","family":"Musumeci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gianmarco Dalla","family":"Zanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Michelucci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bagnoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Nacmias","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Tessa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Rocchiccioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriella","family":"Silvestri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filippo M.","family":"Santorelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,22]]},"reference":[{"key":"874_CR1","unstructured":"McKusick-Nathans Institute of Genetic Medicine Johns Hopkins University (Baltimore M Online Mendelian Inheritance in Man (OMIM). https:\/\/www.omim.org\/"},{"key":"874_CR2","doi-asserted-by":"publisher","first-page":"106564","DOI":"10.1016\/j.nbd.2024.106564","volume":"199","author":"M Fortier","year":"2024","unstructured":"Fortier M, Cauhap\u00e9 M, Buono S et al (2024) Decreasing ganglioside synthesis delays motor and cognitive symptom onset in Spg11 knockout mice. Neurobiol Dis 199:106564","journal-title":"Neurobiol Dis"},{"key":"874_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2025.107836","volume":"218","author":"C Vantaggiato","year":"2025","unstructured":"Vantaggiato C, Guarato G, Brivio F et al (2025) Naringenin and SMER28 target lysosomal reformation and rescue SPG11 and SPG15 hereditary spastic paraplegia phenotypes. Pharmacol Res 218:107836","journal-title":"Pharmacol Res"},{"key":"874_CR4","doi-asserted-by":"publisher","first-page":"1299554","DOI":"10.3389\/fnins.2024.1299554","volume":"18","author":"M H\u00f6rner","year":"2024","unstructured":"H\u00f6rner M, Popp S, Branchu J et al (2024) Clinically approved immunomodulators ameliorate behavioral changes in a mouse model of hereditary spastic paraplegia type 11. Front Neurosci 18:1299554","journal-title":"Front Neurosci"},{"key":"874_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.3389\/fnins.2018.00914","volume":"12","author":"T Pozner","year":"2018","unstructured":"Pozner T, Schray A, Regensburger M et al (2018) Tideglusib rescues neurite pathology of SPG11 iPSC derived cortical neurons. Front Neurosci 12:914","journal-title":"Front Neurosci"},{"key":"874_CR6","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2023.106293","volume":"187","author":"E Chai","year":"2023","unstructured":"Chai E, Chen Z, Mou Y, Thakur G, Zhan W, Li XJ (2023) Liver-X-receptor agonists rescue axonal degeneration in SPG11-deficient neurons via regulating cholesterol trafficking. Neurobiol Dis 187:1062936","journal-title":"Neurobiol Dis"},{"key":"874_CR7","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1080\/15548627.2018.1507438","volume":"15","author":"C Vantaggiato","year":"2019","unstructured":"Vantaggiato C, Panzeri E, Castelli M et al (2019) ZFYVE26\/SPASTIZIN and SPG11\/SPATACSIN mutations in hereditary spastic paraplegia types AR-SPG15 and AR-SPG11 have different effects on autophagy and endocytosis. Autophagy 15:34\u201357","journal-title":"Autophagy"},{"key":"874_CR8","doi-asserted-by":"publisher","DOI":"10.1002\/jimd.12798","volume":"48","author":"HS Dafsari","year":"2025","unstructured":"Dafsari HS, Martinelli D, Saffari A et al (2025) An update on autophagy disorders. J Inherit Metab Dis 48:e12798","journal-title":"J Inherit Metab Dis"},{"key":"874_CR9","doi-asserted-by":"publisher","first-page":"5249","DOI":"10.1172\/JCI77598","volume":"124","author":"J Chang","year":"2014","unstructured":"Chang J, Lee S, Blackstone C (2014) Spastic paraplegia proteins spastizin and Spatacsin mediate autophagic lysosome reformation. J Clin Invest 124:5249\u20135262","journal-title":"J Clin Invest"},{"key":"874_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.nbd.2017.02.007","volume":"102","author":"J Branchu","year":"2017","unstructured":"Branchu J, Boutry M, Sourd L et al (2017) Loss of spatacsin function alters lysosomal lipid clearance leading to upper and lower motor neuron degeneration. Neurobiol Dis 102:21\u201337","journal-title":"Neurobiol Dis"},{"key":"874_CR11","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1002\/acn3.64","volume":"1","author":"B Renvois\u00e9","year":"2014","unstructured":"Renvois\u00e9 B, Chang J, Singh R et al (2014) Lysosomal abnormalities in hereditary spastic paraplegia types\u2009<\u2009scp\u2009>\u2009SPG\u200915 and <\u2009scp\u2009>\u2009SPG\u200911. Ann Clin Transl Neurol 1:379\u2013389","journal-title":"Ann Clin Transl Neurol"},{"key":"874_CR12","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1005454","volume":"11","author":"R-E Varga","year":"2015","unstructured":"Varga R-E, Khundadze M, Damme M et al (2015) In vivo evidence for lysosome depletion and impaired autophagic clearance in hereditary spastic paraplegia type SPG11. PLoS Genet 11:e1005454","journal-title":"PLoS Genet"},{"key":"874_CR13","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1194\/jlr.R003996","volume":"51","author":"Y-H Xu","year":"2010","unstructured":"Xu Y-H, Barnes S, Sun Y, Grabowski GA (2010) Multi-system disorders of glycosphingolipid and ganglioside metabolism. J Lipid Res 51:1643\u20131675","journal-title":"J Lipid Res"},{"key":"874_CR14","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1016\/j.celrep.2018.05.098","volume":"23","author":"M Boutry","year":"2018","unstructured":"Boutry M, Branchu J, Lustremant C et al (2018) Inhibition of lysosome membrane recycling causes accumulation of gangliosides that contribute to neurodegeneration. Cell Rep 23:3813\u20133826","journal-title":"Cell Rep"},{"key":"874_CR15","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1517\/13543784.10.3.455","volume":"10","author":"RH Lachmann","year":"2001","unstructured":"Lachmann RH, Platt FM (2001) Substrate reduction therapy for glycosphingolipid storage disorders. Expert Opin Investig Drugs 10:455\u2013466","journal-title":"Expert Opin Investig Drugs"},{"key":"874_CR16","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.ymgme.2009.12.006","volume":"99","author":"JE Wraith","year":"2010","unstructured":"Wraith JE, Vecchio D, Jacklin E et al (2010) Miglustat in adult and juvenile patients with Niemann\u2013Pick disease type C: long-term data from a clinical trial. Mol Genet Metab 99:351\u2013357","journal-title":"Mol Genet Metab"},{"issue":"Suppl 3","key":"874_CR17","doi-asserted-by":"publisher","first-page":"S355","DOI":"10.1007\/s10545-010-9186-3","volume":"33","author":"M Masciullo","year":"2010","unstructured":"Masciullo M, Santoro M, Modoni A et al (2010) Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type sandhoff: results of a 3-year follow-up. J Inherit Metab Dis 33(Suppl 3):S355\u2013S361","journal-title":"J Inherit Metab Dis"},{"key":"874_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26052195","volume":"26","author":"G Canini","year":"2025","unstructured":"Canini G, Mazzinelli E, Nocca G, Lattanzi W, Arcovito A (2025) Targeting glucosylceramide synthase: innovative drug repurposing strategies for lysosomal diseases. Int J Mol Sci 26:2195","journal-title":"Int J Mol Sci"},{"key":"874_CR19","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1212\/01.wnl.0000228242.53336.90","volume":"67","author":"R Schule","year":"2006","unstructured":"Schule R, Holland-Letz T, Klimpe S et al (2006) The spastic paraplegia rating scale (SPRS): a reliable and valid measure of disease severity. Neurology 67:430\u2013434","journal-title":"Neurology"},{"key":"874_CR20","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1002\/acn3.583","volume":"5","author":"C Wilke","year":"2018","unstructured":"Wilke C, Rattay TW, Hengel H et al (2018) Serum neurofilament light chain is increased in hereditary spastic paraplegias. Ann Clin Transl Neurol 5:876\u2013882","journal-title":"Ann Clin Transl Neurol"},{"key":"874_CR21","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1194\/jlr.M040618","volume":"54","author":"M Fan","year":"2013","unstructured":"Fan M, Sidhu R, Fujiwara H et al (2013) Identification of Niemann-Pick C1 disease biomarkers through sphingolipid profiling. J Lipid Res 54:2800\u20132814","journal-title":"J Lipid Res"},{"key":"874_CR22","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-Hubsch","year":"2006","unstructured":"Schmitz-Hubsch T, du Montcel ST, Baliko L et al (2006) Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology 66:1717\u20131720","journal-title":"Neurology"},{"key":"874_CR23","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1016\/j.nmd.2007.08.003","volume":"17","author":"M Kierkegaard","year":"2007","unstructured":"Kierkegaard M, Tollb\u00e4ck A (2007) Reliability and feasibility of the six minute walk test in subjects with myotonic dystrophy. Neuromuscul Disord 17:943\u2013949","journal-title":"Neuromuscul Disord"},{"key":"874_CR24","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1016\/S0031-9406(05)61264-3","volume":"88","author":"MJ Watson","year":"2002","unstructured":"Watson MJ (2002) Refining the ten-metre walking test for use with neurologically impaired people. Physiotherapy 88:386\u2013397","journal-title":"Physiotherapy"},{"key":"874_CR25","doi-asserted-by":"publisher","first-page":"1860","DOI":"10.1212\/WNL.0b013e318258f744","volume":"78","author":"D Cella","year":"2012","unstructured":"Cella D, Lai J-S, Nowinski CJ et al (2012) Neuro-QOL: brief measures of health-related quality of life for clinical research in neurology. Neurology 78:1860\u20131867","journal-title":"Neurology"},{"key":"874_CR26","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1016\/j.jval.2012.02.008","volume":"15","author":"B van Hout","year":"2012","unstructured":"van Hout B, Janssen MF, Feng Y-S et al (2012) Interim scoring for the EQ-5D-5L: mapping the EQ-5D-5L to EQ-5D-3L value sets. Value Health 15:708\u2013715","journal-title":"Value Health"},{"key":"874_CR27","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1007\/s10072-014-1921-3","volume":"36","author":"S Conti","year":"2015","unstructured":"Conti S, Bonazzi S, Laiacona M et al (2015) Montreal cognitive assessment (MoCA)-Italian version: regression based norms and equivalent scores. Neurol Sci 36:209\u2013214","journal-title":"Neurol Sci"},{"key":"874_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/s19102227","volume":"19","author":"A Coni","year":"2019","unstructured":"Coni A, Mellone S, Colpo M et al (2019) An exploratory factor analysis of sensor-based physical capability assessment. Sensors (Basel) 19:2227","journal-title":"Sensors (Basel)"},{"key":"874_CR29","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1016\/S1474-4422(07)70194-1","volume":"6","author":"MC Patterson","year":"2007","unstructured":"Patterson MC, Vecchio D, Prady H et al (2007) Miglustat for treatment of Niemann-Pick C disease: a randomised controlled study. Lancet Neurol 6:765\u2013772","journal-title":"Lancet Neurol"},{"key":"874_CR30","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1186\/s13023-019-0996-6","volume":"14","author":"M Pineda","year":"2019","unstructured":"Pineda M, Jur\u00ed\u010dkov\u00e1 K, Karimzadeh P et al (2019) Disease characteristics, prognosis and miglustat treatment effects on disease progression in patients with Niemann-Pick disease type C: an international, multicenter, retrospective chart review. Orphanet J Rare Dis 14:32","journal-title":"Orphanet J Rare Dis"},{"key":"874_CR31","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s13023-020-01363-2","volume":"15","author":"MC Patterson","year":"2020","unstructured":"Patterson MC, Mengel E, Vanier MT et al (2020) Treatment outcomes following continuous miglustat therapy in patients with Niemann-Pick disease type C: a final report of the NPC registry. Orphanet J Rare Dis 15:104","journal-title":"Orphanet J Rare Dis"},{"key":"874_CR32","doi-asserted-by":"publisher","first-page":"12993","DOI":"10.1038\/s41598-021-92406-6","volume":"11","author":"R Tsonaka","year":"2021","unstructured":"Tsonaka R, Seyer A, Aartsma-Rus A, Spitali P (2021) Plasma lipidomic analysis shows a disease progression signature in Mdx mice. Sci Rep 11:12993","journal-title":"Sci Rep"},{"key":"874_CR33","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232113466","volume":"23","author":"C Kessler","year":"2022","unstructured":"Kessler C, Ruschil C, Abdelhak A et al (2022) Serum neurofilament light chain and glial fibrillary acidic protein as biomarkers in primary progressive multiple sclerosis and hereditary spastic paraplegia type 4. Int J Mol Sci 23:13466","journal-title":"Int J Mol Sci"},{"key":"874_CR34","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/mds.29755","volume":"39","author":"L Krumm","year":"2024","unstructured":"Krumm L, Winkler J, Winner B, Regensburger M (2024) Plasma neurofilaments: potential biomarkers of SPG11-related hereditary spastic paraplegia. Mov Disord 39:755\u2013757","journal-title":"Mov Disord"},{"key":"874_CR35","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/brain\/awm293","volume":"131","author":"G Stevanin","year":"2008","unstructured":"Stevanin G, Azzedine H, Denora P et al (2008) Mutations in SPG11 are frequent in autosomal recessive spastic paraplegia with thin corpus callosum, cognitive decline and lower motor neuron degeneration. Brain 131:772\u2013784","journal-title":"Brain"},{"key":"874_CR36","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1089\/jpm.2023.0294","volume":"27","author":"Y Li","year":"2024","unstructured":"Li Y, Hung V, Ho K et al (2024) The validity of patient-reported outcome measures of quality of life in palliative care: a systematic review. J Palliat Med 27:545\u2013562","journal-title":"J Palliat Med"},{"key":"874_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s40900-023-00535-1","volume":"10","author":"P Furlong","year":"2024","unstructured":"Furlong P, Dugar A, White M (2024) Patient engagement in clinical trial design for rare neuromuscular disorders: impact on the DELIVER and ACHIEVE clinical trials. Res Involv Engagem 10:1","journal-title":"Res Involv Engagem"},{"key":"874_CR38","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.3390\/ijms17071065","volume":"17","author":"MF Coutinho","year":"2016","unstructured":"Coutinho MF, Santos JI, Alves S (2016) Less is more: substrate reduction therapy for lysosomal storage disorders. Int J Mol Sci 17:1065","journal-title":"Int J Mol Sci"},{"key":"874_CR39","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/j.ymthe.2019.05.018","volume":"27","author":"J Marshall","year":"2019","unstructured":"Marshall J, Nietupski JB, Park H et al (2019) Substrate reduction therapy for Sandhoff disease through inhibition of glucosylceramide synthase activity. Mol Ther 27:1495\u20131506","journal-title":"Mol Ther"},{"key":"874_CR40","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1002\/mds.29398","volume":"38","author":"A Schidlitzki","year":"2023","unstructured":"Schidlitzki A, Stanojlovic M, Fournier C et al (2023) Double-edged effects of venglustat on behavior and pathology in mice overexpressing \u03b1-synuclein. Mov Disord 38:1044\u20131105","journal-title":"Mov Disord"},{"key":"874_CR41","doi-asserted-by":"publisher","first-page":"2907","DOI":"10.1007\/s12325-024-02881-2","volume":"41","author":"R Schiffmann","year":"2024","unstructured":"Schiffmann R, Mengel E, Wallace M et al (2024) Qualitative study of the patient experience with venglustat for gaucher disease type 3 in a phase 2 open-label, multicenter, multinational study (LEAP). Adv Ther 41:2907\u20132923","journal-title":"Adv Ther"},{"key":"874_CR42","doi-asserted-by":"publisher","first-page":"557","DOI":"10.3233\/JPD-212714","volume":"12","author":"MJ Peterschmitt","year":"2022","unstructured":"Peterschmitt MJ, Saiki H, Hatano T et al (2022) Safety, pharmacokinetics, and pharmacodynamics of oral venglustat in patients with Parkinson\u2019s disease and a GBA mutation: results from part 1 of the randomized, double-blinded, placebo-controlled MOVES-PD trial. J Parkinsons Dis 12:557\u2013570","journal-title":"J Parkinsons Dis"}],"container-title":["Neurogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-025-00874-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10048-025-00874-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10048-025-00874-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,23]],"date-time":"2026-05-23T09:02:00Z","timestamp":1779526920000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10048-025-00874-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,22]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["874"],"URL":"https:\/\/doi.org\/10.1007\/s10048-025-00874-z","relation":{},"ISSN":["1364-6753"],"issn-type":[{"value":"1364-6753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,22]]},"assertion":[{"value":"28 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The affiliation \"Department of Neurosciences, Universit\u00e0 Cattolica del Sacro Cuore, Rome, Italy\" has been incorrectly affiliated to Serana Mero. The correct affilitaion for Serana Mero is Molecular Medicine for Neurodegenerative and Neuromuscular Diseases Unit, IRCCS Fondazione Stella Maris, via dei Giacinti 2, Pisa, Italy.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Tuscany Regional Pediatric Ethics Committee and written informed consent was obtained from the patients.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"3"}}